Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.00 Average Target Price from Analysts

Astria Therapeutics, Inc. (NASDAQ:ATXS) has been assigned a consensus recommendation of “Hold” from the ten research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and three have given a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $25.00.

A number of analysts recently weighed in on the stock. Wedbush set a $13.00 target price on shares of Astria Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Cantor Fitzgerald restated an “overweight” rating and set a $49.00 target price on shares of Astria Therapeutics in a research report on Wednesday, September 17th. Citizens Jmp cut Astria Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 15th. Oppenheimer lowered Astria Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, October 14th. Finally, HC Wainwright cut shares of Astria Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, October 16th.

Astria Therapeutics Stock Down 0.8%

Shares of NASDAQ:ATXS opened at $12.51 on Friday. Astria Therapeutics has a 52-week low of $3.56 and a 52-week high of $12.72. The stock has a market cap of $706.00 million, a P/E ratio of -6.22 and a beta of 0.21. The business has a fifty day moving average of $9.55 and a two-hundred day moving average of $7.07.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.57) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.04. On average, equities analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Trading of Astria Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the business. Farther Finance Advisors LLC raised its holdings in shares of Astria Therapeutics by 185.8% in the 2nd quarter. Farther Finance Advisors LLC now owns 5,471 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,557 shares during the period. Cubist Systematic Strategies LLC grew its stake in shares of Astria Therapeutics by 503.7% during the first quarter. Cubist Systematic Strategies LLC now owns 92,239 shares of the biotechnology company’s stock valued at $493,000 after acquiring an additional 76,961 shares in the last quarter. Hsbc Holdings PLC raised its position in shares of Astria Therapeutics by 70.3% in the 1st quarter. Hsbc Holdings PLC now owns 32,808 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 13,545 shares in the last quarter. Nuveen LLC bought a new stake in shares of Astria Therapeutics in the 1st quarter worth about $553,000. Finally, Wellington Management Group LLP grew its position in shares of Astria Therapeutics by 3.1% in the 1st quarter. Wellington Management Group LLP now owns 152,611 shares of the biotechnology company’s stock worth $815,000 after acquiring an additional 4,562 shares in the last quarter. 98.98% of the stock is owned by institutional investors and hedge funds.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.